Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Marcenaro

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
JCI Insight|November 6, 2019
NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancerJoanna Mikulak, Ferdinando Oriolo, Elena Bruni, et al.
Frontiers in Immunology|November 22, 2021
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK CellsFabio Guolo, Paola Minetto, Silvia Pesce, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Nature|October 25, 2021
Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cellsMario Witkowski, Caroline Tizian, Marta Ferreira-Gomes, et al.
Cancer Cell|September 13, 2022
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancerBérengère Salomé, John P Sfakianos, Daniel Ranti, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Frontiers in Immunology|August 4, 2017
Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
JCI Insight|November 6, 2019
NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancerJoanna Mikulak, Ferdinando Oriolo, Elena Bruni, et al.
Frontiers in Immunology|November 22, 2021
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK CellsFabio Guolo, Paola Minetto, Silvia Pesce, et al.
Blood Advances|November 26, 2019
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AMLBérengère Salomé, Alejandra Gomez-Cadena, Romain Loyon, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Nature Communications|September 21, 2017
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axisSara Trabanelli, Mathieu F Chevalier, Amaia Martinez-Usatorre, et al.
Nature|October 25, 2021
Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cellsMario Witkowski, Caroline Tizian, Marta Ferreira-Gomes, et al.
Cancer Cell|September 13, 2022
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancerBérengère Salomé, John P Sfakianos, Daniel Ranti, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Frontiers in Immunology|August 4, 2017
Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 11